透過您的圖書館登入
IP:3.15.143.181
  • 期刊
  • OpenAccess

Gelsolin and Non-Alcoholic Fatty Liver Disease in Hemodialysis Patients

摘要


BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) has emerged as a global health problem. As NAFLD advances, the risks of developing more serious diseases such as cirrhosis, hepatocellular carcinoma, and cardiovascular diseases (CVD) also increase. In hemodialysis (HD) patients, NAFLD is more prevalent and is strongly associated with CVD. Plasma gelsolin (pGSN), a multi-functional protein, has been implicated in modulation of the immune system, inflammation, and metabolic syndrome. Its deficiency is correlated with HD mortality and vascular complications. The aim of this study was to investigate the association between pGSN levels and NAFLD in HD patients. METHODS: We measured pGSN levels and biochemical profiles in 110 stable HD patients, and characterized their fatty liver status with ultrasonography. RESULTS: Patients with NAFLD (n = 74) had higher body mass index, waist circumference and lower high-density lipoprotein, pGSN levels than the non-fatty liver group. Logistic regression analysis demonstrated pGSN to bethe independent factor associated with NAFLD (odd ratio, 1.21, 95% CI, 1.01-1.44, P = 0.036). pGSN is correlated with liver function tests, albumin, and vascular disease. CONCLUSION: The associations of pGSN and NAFLD in HD patients warrants further validation and investigation, and may pave new pathways for future research in chronic liver and kidney diseases.

延伸閱讀